

Parkinson's Disease - Pipeline Review, H2 2020

<https://marketpublishers.com/r/PD6E3AB23608EN.html>

Date: October 2020

Pages: 1308

Price: US\$ 2,500.00 (Single User License)

ID: PD6E3AB23608EN

Abstracts

Parkinson's Disease - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Parkinson's Disease - Pipeline Review, H2 2020, provides an overview of the Parkinson's Disease (Central Nervous System) pipeline landscape.

Parkinson's disease (PD) is a neurodegenerative disorder characterized by movement dysfunctions. The main finding in brains of people with PD is loss of dopaminergic neurons in substantia nigra. Symptoms generally develop slowly over years. People with PD experience dyskinesia, dystonia, tremor, stiffness and impaired locomotory functions. Risk factors include age, genetic factors, environmental factors and gender. Treatment options include anticholinergics, COMT inhibitors and dopamine agonists.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Parkinson's Disease - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Parkinson's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Parkinson's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Parkinson's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and

Unknown stages are 3, 11, 48, 62, 4, 224, 97 and 9 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1, 52 and 19 molecules, respectively.

Parkinson's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Parkinson's Disease (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Parkinson's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Parkinson's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Parkinson's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Parkinson's Disease (Central Nervous System)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Parkinson's Disease (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Parkinson's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Parkinson's Disease - Overview

Parkinson's Disease - Therapeutics Development

Parkinson's Disease - Therapeutics Assessment

Parkinson's Disease - Companies Involved in Therapeutics Development

Parkinson's Disease - Drug Profiles

Parkinson's Disease - Dormant Projects

Parkinson's Disease - Discontinued Products

Parkinson's Disease - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Parkinson's Disease, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Parkinson's Disease - Pipeline by 1st Bio Therapeutics Inc, H2 2020
Parkinson's Disease - Pipeline by 4D Pharma Plc, H2 2020
Parkinson's Disease - Pipeline by Abaxy Sprl, H2 2020
Parkinson's Disease - Pipeline by AbbVie Inc, H2 2020
Parkinson's Disease - Pipeline by Abfero Pharmaceuticals Inc, H2 2020
Parkinson's Disease - Pipeline by Abivax SA, H2 2020
Parkinson's Disease - Pipeline by ABL Bio Inc, H2 2020
Parkinson's Disease - Pipeline by AC Immune SA, H2 2020
Parkinson's Disease - Pipeline by Accure Therapeutics SL, H2 2020
Parkinson's Disease - Pipeline by Acelot Inc, H2 2020
Parkinson's Disease - Pipeline by Addex Therapeutics Ltd, H2 2020
Parkinson's Disease - Pipeline by Adicet Bio Inc, H2 2020
Parkinson's Disease - Pipeline by Affichem SA, H2 2020
Parkinson's Disease - Pipeline by AFFiRiS AG, H2 2020
Parkinson's Disease - Pipeline by Carmot Therapeutics Inc, H2 2020
Parkinson's Disease - Pipeline by Carna Biosciences Inc, H2 2020
Parkinson's Disease - Pipeline by Casma Therapeutics Inc, H2 2020
Parkinson's Disease - Pipeline by Cavion LLC, H2 2020
Parkinson's Disease - Pipeline by CavoGene LifeSciences, H2 2020
Parkinson's Disease - Pipeline by Celavie Biosciences LLC, H2 2020
Parkinson's Disease - Pipeline by CellCure, H2 2020
Parkinson's Disease - Pipeline by Cellivery Therapeutics Inc, H2 2020
Parkinson's Disease - Pipeline by Cellix Bio Pvt Ltd, H2 2020
Parkinson's Disease - Pipeline by Cerecin Inc, H2 2020
Parkinson's Disease - Pipeline by Cerecor Inc, H2 2020
Parkinson's Disease - Pipeline by CereSpir Inc, H2 2020

Parkinson's Disease - Pipeline by Cerevance Inc, H2 2020

Parkinson's Disease - Pipeline by Cerevel Therapeutics LLC, H2 2020

Parkinson's Disease - Pipeline by CHA Biotech Co Ltd, H2 2020

Parkinson's Disease - Pipeline by Chamishi Therapeutics Inc, H2 2020

Parkinson's Disease - Pipeline by Chase Therapeutics Corp, H2 2020

Parkinson's Disease - Pipeline by Chiesi Farmaceutici SpA, H2 2020

Parkinson's Disease - Pipeline by CholesteniX Ltd, H2 2020

Parkinson's Disease - Pipeline by Chongqing Pharmaceutical Research Institute Co Ltd, H2 2020

Parkinson's Disease - Pipeline by Ci Therapeutics, H2 2020

Parkinson's Disease - Pipeline by Clayton Biotechnologies Inc, H2 2020

Parkinson's Disease - Pipeline by Clene Nanomedicine Inc, H2 2020

Parkinson's Disease - Pipeline by Clevexel Pharma SA, H2 2020

Parkinson's Disease - Pipeline by InnoMedica Holding AG, H2 2020

Parkinson's Disease - Pipeline by Intec Pharma Ltd, H2 2020

Parkinson's Disease - Pipeline by International Stem Cell Corp, H2 2020

Parkinson's Disease - Pipeline by Intra-Cellular Therapies Inc, H2 2020

Parkinson's Disease - Pipeline by Invisio Ltd, H2 2020

Parkinson's Disease - Pipeline by Io Therapeutics Inc, H2 2020

Parkinson's Disease - Pipeline by Ionis Pharmaceuticals Inc, H2 2020

Parkinson's Disease - Pipeline by IRLAB Therapeutics AB, H2 2020

Parkinson's Disease - Pipeline by Jazz Pharmaceuticals Plc, H2 2020

Parkinson's Disease - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2020

Parkinson's Disease - Pipeline by Junaxo Inc, H2 2020

Parkinson's Disease - Pipeline by Kainos Medicine Inc, H2 2020

Parkinson's Disease - Pipeline by Kariya Pharmaceuticals IVS, H2 2020

Parkinson's Disease - Dormant Projects, H2 2020

Parkinson's Disease - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Parkinson's Disease, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020

I would like to order

Product name: Parkinson's Disease - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/PD6E3AB23608EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PD6E3AB23608EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970